Zobrazeno 1 - 10
of 618
pro vyhledávání: '"David H. JOHNSON"'
Publikováno v:
BMC Ecology and Evolution, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background Core landbirds undergo adaptive radiation with different ecological niches, but the genomic bases that underlie their ecological diversification remain unclear. Results Here we used the genome-wide target enrichment sequencing of
Externí odkaz:
https://doaj.org/article/76e40545f15547a9b96bac88d2a391d8
Autor:
Melanie S. Sulistio, Amit Khera, Kathryn Squiers, Monika Sanghavi, Colby R. Ayers, Weifeng Weng, Salahuddin Kazi, James de Lemos, David H. Johnson, Lynne Kirk
Publikováno v:
BMC Medical Education, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Though the proportion of female Internal Medicine (IM) residents and faculty has increased, there is minimal large scale modern data comparing resident performance by gender. This study sought to examine the effects of resident an
Externí odkaz:
https://doaj.org/article/861f34c443a34bf382918870900a15df
Autor:
Giuseppe GIACCONE, David TRENT, John R. STRAWN, Reily SMITH, Thomas J. SMITH, Joan H. SCHILLER, David G. PFISTER, Steven PIANTADOSI, Luke NORDQUIST, Daniel MILTON, Gregory MASTERS, Janessa L. LASKI, David H. JOHNSON, Julie BRAHMER, William PAO, Timothy ALIFF, Sarah TEMIN, Sherman Baker JR, Christopher G. AZZOLI
Publikováno v:
Chinese Journal of Lung Cancer, Vol 13, Iss 3, Pp 171-189 (2010)
Externí odkaz:
https://doaj.org/article/4c40e597843b41f7b295cbd8bfd46afe
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Simon J. Craddock Lee, Jessica Lee, Hong Zhu, Patricia M. Chen, Urooj Wahid, Heidi A. Hamann, Sheena Bhalla, Rodrigo Catalan Cardenas, Vijaya Subbu Natchimuthu, David H. Johnson, Noel O. Santini, Himani R. Patel, David E. Gerber
Publikováno v:
Population Health Management.
Supplementary Figure S1 from Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff49ba931b0ea409807c915349e1eb1
https://doi.org/10.1158/1078-0432.22441260.v1
https://doi.org/10.1158/1078-0432.22441260.v1
Autor:
Ignacio I. Wistuba, John D. Minna, Guanghua Xiao, Vassiliki A. Papadimitrakopoulou, John V. Heymach, Stephen G. Swisher, David H. Johnson, Qinghua Zhou, Jack A. Roth, Carmen Behrens, Cesar Moran, Yunyun Zhou, Hao Tang, Ximing Tang, Shidan Wang, Wei Lu, Yang Xie
Supplementary Table S1. Summary of Tables and Figures. Supplementary Table S2. Propensity score-matched coefficients for each variable using logistic regression. Supplementary Table S3. Propensity score matching results. In Supplementary Table 4. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7edb40de6a74448105be433cf1147b75
https://doi.org/10.1158/1078-0432.22467194
https://doi.org/10.1158/1078-0432.22467194
Background: E4599 was a phase II/phase III trial, in which 878 patients with advanced non–small cell lung cancer were randomized to carboplatin + paclitaxel (PC arm) or PC + bevacizumab (BPC arm). Survival and progression-free survival were superio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::537ba35154ca99d88eb38097c7ca8766
https://doi.org/10.1158/1078-0432.c.6518373.v1
https://doi.org/10.1158/1078-0432.c.6518373.v1
Autor:
David P. Carbone, David H. Johnson, Jason D. Morrow, Sorena Nadaf, Nobuhiro Haruki, Kiyoshi Yanagisawa, Ildiko Csiki
Hypoxic induction of gene expression occurs mainly via the hypoxia-inducible factor-1 (HIF-1) transcription factor and is a critical step in tumor growth. Cyclooxygenase-2 (COX-2) is commonly overexpressed in non–small cell lung cancer (NSCLC). In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::928a1980602558fc2c3e63ef6ae81e94
https://doi.org/10.1158/0008-5472.c.6494415
https://doi.org/10.1158/0008-5472.c.6494415
Autor:
David P. Carbone, David H. Johnson, Jason D. Morrow, Sorena Nadaf, Nobuhiro Haruki, Kiyoshi Yanagisawa, Ildiko Csiki
Supplementary Figures 1-3 from Thioredoxin-1 Modulates Transcription of Cyclooxygenase-2 via Hypoxia-Inducible Factor-1α in Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0984c156def4afaa9fd9abfd430ec7a0
https://doi.org/10.1158/0008-5472.22364883.v1
https://doi.org/10.1158/0008-5472.22364883.v1